Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Tectonic Operating Company, Inc.
Study ID
NCT07473700
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Hypertension, Pulmonary
  • Lung Diseases, Interstitial

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • TX000045 — DRUG
    Subcutaneous Injection.

Study Details

The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and tolerability of TX000045 in participants with PH-ILD.

Key Dates

First listed
Mar 16, 2026
Start date
Aug 31, 2026
Status verified
Jul 2026
Primary completion
Nov 21, 2027
Completion
Dec 11, 2027

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TX000045 300 mg
    Participants will receive subcutaneous (SC) injection of TX000045 at a dose of 300 milligrams (mg) every 4 weeks (Q4W) from Week 1 up to Week 13.

Primary Outcome Measure

Mean Change from Baseline in PVR up to 16 Weeks [ Time Frame: Baseline up to 16 weeks ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
PhoenixPhoenixArizona85020-
San FranciscoSan FranciscoCalifornia94143-
IdahoIdaho FallsIdaho83706-
Allen ParkAllen ParkMichigan48101-

Find similar trials in Phoenix, AZ

By research site
Phoenix· Phoenix, AZSan Francisco· San Francisco, CAIdaho· Idaho Falls, IDAllen Park· Allen Park, MI

Related Studies